Characterization of complement‐fixing antibodies to peripheral nerve myelin in Guillain‐Barré syndrome

No abstract is available for this paper.

• Publication year

  1990

• Venue

  Annals of Neurology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/ana.410270712PMID 2194426
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Experimental allergic encephalomyelitis: the balance between encephalitogenic T lymphocytes and demyelinating antibodies determines size and structure of demyelinated lesions

  2004cited by this paper
• The role of complement in the pathogenesis of experimental allergic encephalomyelitis.

  1989cited by this paper
• Anti-peripheral nerve myelin antibodies in Guillain-Barre syndrome bind a neutral glycolipid of peripheral myelin and cross-react with Forssman antigen.

  1989cited by this paper
• Serum antibodies to gangliosides in guillain‐barré syndrome

  1988cited by this paper
• Guillain‐barré syndrome

  1987cited by this paper
• Activation of terminal components of complement in patients with Guillain-Barré syndrome and other demyelinating neuropathies.

  1987cited by this paper
• Clinical correlation with anti‐peripheral‐nerve myelin antibodies in Guillain‐Barré syndrome

  1986cited by this paper
• Activated terminal complement in cerebrospinal fluid in Guillain-Barré syndrome and multiple sclerosis.

  1986cited by this paper
• Activation of the alternative pathway of complement by human peripheral nerve myelin.

  1985cited by this paper
• Quantitation of activation of the human terminal complement pathway by ELISA.

  1985cited by this paper
• Anti-peripheral myelin antibody in patients with demyelinating neuropathy: quantitative and kinetic determination of serum antibody by complement component 1 fixation.

  1985cited by this paper
• Complement‐fixing antiperipheral nerve myelin antibodies in patients with inflammatory polyneuritis and with polyneuropathy and paraproteinemia

  1981cited by this paper
• Heterophile antigens and antibodies in medicine.

  1977cited by this paper
• Thirty-eight Cases of the Guillain-Barré Syndrome: An Immunological Study

  1963cited by this paper

• Predictors of the Short‐Term Outcomes of Guillain–Barré Syndrome: Exploring Electrodiagnostic and Clinical Features

  2025cites this paper
• Application of optogenetic glial cells to neuron–glial communication

  2023cites this paper
• Comparison of the Efficacy of Optogenetic Stimulation of Glia versus Neurons in Myelination.

  2020cites this paper
• The role of primary infection of Schwann cells in the aetiology of infective inflammatory neuropathies.

  2016cites this paper
• The Inflammatory Demyelinating Neuropathies

  2015cites this paper
• A review of the use of biological agents for chronic inflammatory demyelinating polyradiculoneuropathy.

  2013cites this paper
• Antibodies against GM1 gangliosides associated with metastatic melanoma.

  2013cites this paper
• Innate immunity in the nervous system.

  2009cites this paper
• Anti-GD1a antibody targeted disruption of the node of Ranvier in a mouse model of acute motor axonal neuropathy

  2009cites this paper
• The complement system in the peripheral nerve: friend or foe?

  2008cites this paper
• Noninfectious inflammatory central nervous system diseases in dogs.

  2007cites this paper
• Pathological features of ganglioradiculitis (sensory neuropathy) in two dogs.

  2007cites this paper
• Current Therapeutic Options in Severe Guillain-Barre´ Syndrome

  2006influential citation
• Myelin‐ and microbe‐specific antibodies in guillain‐barré syndrome

  2005cites this paper
• Guillain-Barré syndrome: clinical and immunological aspects

  2004cites this paper
• High-dose intravenous immunoglobulin in the treatment of Guillain-Barré syndrome: a preliminary open study

  2004cites this paper
• Immunolocalization and activation of transcription factor nuclear factor kappa B in dysimmune neuropathies and familial amyloidotic polyneuropathy.

  2004cites this paper
• The membrane attack complex of complement mediates peripheral nervous system demyelination in vitro

  2004cites this paper
• Expression of complement components in the peripheral nervous system.

  2003cites this paper
• Genetic profiling of the peripheral nervous system

  2003cites this paper
• Outcome of Severe Guillain–Barré Syndrome in Children: Comparison Between Untreated Cases Versus Gamma-Globulin Therapy

  2003cites this paper
• Chronic inflammatory demyelinating polyradiculoneuropathy.

  2002cites this paper
• Advances in Neurobiology of the Neuromuscular Junction: Implications for the Anesthesiologist

  2002cites this paper
• CD4 and CD8 T cells, but not B cells, are critical to the control of murine experimental autoimmune neuritis.

  2002cites this paper
• Anti-GM(2) IgM antibody-induced complement-mediated cytotoxicity in patients with dysimmune neuropathies.

  2001cites this paper
• Advances in Neurobiology of the Neuromuscular Junction

  2001cites this paper
• Glial cells as targets for cytotoxic immune mediators

  2001cites this paper
• Cutting Edge: C3, a Key Component of Complement Activation, Is Not Required for the Development of Myelin Oligodendrocyte Glycoprotein Peptide-Induced Experimental Autoimmune Encephalomyelitis in Mice1

  2001cites this paper
• Autoimmune Encephalomyelitis in Mice Glycoprotein Peptide-Induced Experimental the Development of Myelin Oligodendrocyte Complement Activation , Is Not Required for Cutting Edge : C 3 , a Key Component of Abdolmohamad

  2000influential citation
• Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients

  2000cites this paper
• Immunohistochemical localization of cytokines, C5b-9 and ICAM-1 in peripheral nerve of Guillain-Barré syndrome.

  2000cites this paper
• Detection of an Autoantibody from Pug Dogs with Necrotizing Encephalitis (Pug Dog Encephalitis)

  1999cites this paper
• Myelinated dorsal root ganglion cultures activate both the alternative and classical pathways of complement.

  1999cites this paper
• Mechanisms of Immune Regulation in the Peripheral Nervous System

  1999cites this paper
• Pathogenesis of Guillain-Barré syndrome.

  1999cites this paper
• Antiganglioside GM1 Antibodies and Their Complement Activating Capacity in Central and Peripheral Nervous System Disorders and in Controls

  1998cites this paper
• Therapeutic inhibition of the complement system.

  1998cites this paper
• Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy

  1998cites this paper
• Clomipramine and imipramine suppress clinical signs and T and B cell response to myelin proteins in experimental autoimmune neuritis in Lewis rats.

  1998cites this paper
• Pathogenesis of neuroimmunologic diseases

  1998cites this paper
• The Role of Macrophages in Wallerian Degeneration

  1997cites this paper
• Antecedent infections and anti-ganglioside antibodies in Guillain-Barré syndrome : their role in pathogenesis and heterogeneity

  1997cites this paper
• Mechanisms of Schwann cell damage in inflammatory neuropathy.

  1997cites this paper
• Immune globulins are effective in severe pediatric Guillain-Barré syndrome.

  1997cites this paper
• The role of complement in disorders of the nervous system.

  1997cites this paper
• Effector mechanisms in demyelinating neuropathies.

  1996cites this paper
• Guillain-Barré as an autoimmune disease.

  1996cites this paper
• Immunopathogenesis and treatment of the guillain‐barré syndrome—part I

  1995cites this paper
• Physiology and Pathophysiology of Complement: Progress and Trends

  1995cites this paper
• Physiology and pathophysiology of complement: progress and trends.

  1995cites this paper
• Circulating adhesion molecules and inflammatory mediators in demyelination

  1995cites this paper
• Clinical complementology: recent progress and future trends

  1994cites this paper
• Antibody of patients with Guillain-Barré syndrome mediates complement-dependent cytolysis of rat Schwann cells: susceptibility to cytolysis reflects Schwann cell phenotype.

  1994cites this paper
• Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy: Pathogenesis and Treatment

  1994cites this paper
• Widenings of the myelin lamellae in a typical Guillain–Barré syndrome

  1994cites this paper
• Central autonomic dysorganization in the early stages of experimental meningitis in rabbits induced by complement-C5A-fragment: a pathophysiological validation of the largest lyapunov exponent of heart rate dynamics.

  1994cites this paper
• Guillain-Barré syndrome and CIDP

  1994cites this paper
• Central Autonomic Dysorganization in the Early Stages of Experimental Meningitis in Rabbits Induced by Complement-C5A-Fragment: A Pathophysiological Validation of the Largest Lyapunov Exponent of Heart Rate Dynamics

  1994cites this paper
• Acute polyradiculoneuritis associated with cytomegalovirus infection in renal transplantation

  1993cites this paper
• Guillain-Barré syndrome following immunisation withHaemophilus influenzae type b conjugate vaccine

  1993cites this paper
• IgG monoclonal paraproteinaemia and peripheral neuropathy.

  1993cites this paper
• Pathogenesis of Immune-Mediated Neuropathies

  1993cites this paper
• Complement in diseases of the nervous system

  1993cites this paper
• Seric immune complexes in multiple sclerosis do not contain MBP epitopes.

  1993cites this paper
• The role of macrophages in degeneration and immune-mediated demyelination of the peripheral nervous system

  1992cites this paper
• Inflammatory mediators in demyelinating disorders of the CNS and PNS.

  1992cites this paper
• Humoral mechanisms in immune neuropathies.

  1992cites this paper
• Clinical and serological studies in a series of 45 patients with Guillain-Barré syndrome.

  1991cites this paper
• Kinetics of anti-peripheral nerve myelin antibody in patients with Guillain-Barré syndrome treated and not treated with plasmapheresis.

  1991cites this paper
• Antibody-mediated neurological disease.

  1991cites this paper
• Presence of the terminal complement complex (C5b‐9) precedes myelin degradation in immune‐mediated demyelination of the rat peripheral nervous system

  1991cites this paper
• Immunological parameters in Guillain‐Barré syndrome

  1990cites this paper